← Back to Search

Other

Low-level laser for Lymphedema

N/A
Waitlist Available
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8-week post-lllt
Awards & highlights

Summary

This trial is testing low-level laser treatment (LLLT) on head and neck cancer survivors who have lymphedema. LLLT uses light to reduce swelling and improve blood flow, which may help with symptoms like tightness and limited movement. The study aims to see if LLLT can improve their quality of life. Low-level laser therapy (LLLT) has been studied for its effects on reducing inflammation, promoting tissue repair, and relieving pain in various conditions, including breast cancer-related lymphedema.

Eligible Conditions
  • Lymphedema
  • Head and Neck Cancers
  • Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8-week post-lllt
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8-week post-lllt for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
% of patients with reduced severity of lymphedema and fibrosis
Secondary outcome measures
Neck
Quality of life score
Symptom burden score

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1 (laser group)Experimental Treatment1 Intervention
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Group II: Group 2 (wait-list control group)Active Control1 Intervention
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Low-level laser
2020
N/A
~230

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
396 Previous Clinical Trials
147,940 Total Patients Enrolled
3 Trials studying Lymphedema
564 Patients Enrolled for Lymphedema
University of PennsylvaniaLead Sponsor
2,027 Previous Clinical Trials
42,885,685 Total Patients Enrolled
3 Trials studying Lymphedema
371 Patients Enrolled for Lymphedema
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top